SCHEMBL930766

SCHEMBL930766

N#Cc1cc(-c2nccs2)nc(N)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.53
ADORA2A P29274 4/20 0.41
ADORA1 P30542 3/20 0.41
RAB9A P51151 1/20 0.36
HPGD P15428 3/20 0.35
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
NOS1 P29475 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CYP1A1 P04798 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP1B1 Q16678 2/20 0.34
DAPK3 O43293 1/20 0.34
MAP4K4 O95819 1/20 0.34
PRKACA P17612 1/20 0.34
LTK P29376 1/20 0.34
MAPK8 P45983 1/20 0.34
CSNK1A1 P48729 1/20 0.34
CDK8 P49336 1/20 0.34
CLK2 P49760 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20416542 0.84 HSP90AA1 (0.53) HSP90AA1ADORA2AADORA1RAB9AHPGD
SCHEMBL20416543 0.80 HSP90AA1 (0.48) HSP90AA1ADORA2AADORA1RAB9AHPGD
SCHEMBL929763 0.77 HSP90AA1 (0.59) HSP90AA1ADORA2AADORA1RAB9AHPGD
SCHEMBL929587 0.76 HSP90AA1 (0.57) HSP90AA1ADORA2AADORA1RAB9AALDH1A1
SCHEMBL30252385 0.73 HSP90AA1 (0.43) HSP90AA1ADORA2AADORA1RAB9AHPGD
SCHEMBL20911193 0.73 HSP90AA1 (0.43) HSP90AA1ADORA2AADORA1RAB9AHPGD
SCHEMBL30252529 0.72 HSP90AA1 (0.56) HSP90AA1ADORA2AADORA1RAB9AHPGD
SCHEMBL20911504 0.72 HSP90AA1 (0.42) HSP90AA1ADORA2AADORA1RAB9AHPGD
SCHEMBL30253041 0.72 HSP90AA1 (0.42) HSP90AA1ADORA2AADORA1RAB9AHPGD
SCHEMBL929516 0.71 HSP90AA1 (0.51) HSP90AA1ADORA2AADORA1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875600-B2 Pyrimidine compounds as purine receptor antagonist VERNALIS (R&D) LIMITED (GB) 2011-01-25 US disclosed
US-20070281936-A1 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide VERNALIS (R & D ) LIMITED (GB) 2007-12-06 US disclosed
EP-1720553-A1 PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST VERNALIS (R&D) LTD (GB) 2006-11-15 EP disclosed
WO-2005079801-A1 PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST VERNALIS (R & D) LTD (GB) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281936-A1 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide ADORA2A, ADORA3, ADORA1 HSP90AA1 4430/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.